The Coalition for Epidemic Preparedness Innovations (CEPI) was officially launched at World Economic Forum (WEF) Davos after it received $460-million to develop vaccines against 3 emerging highly-contagious and fatal diseases.
These three diseases are Middle East respiratory syndrome (MERS)-coronavirus, Lassa fever, and Nipah virus. CEPI will use this fund to contain outbreaks these 3 diseases before they become global health emergencies.
- Under it, CEPI will solicit proposals from academic researchers and industry to develop candidate vaccines for its three target viruses.
- In 5 years, it aims develop at least two vaccines for each virus through early human studies so that they are ready for a real-world test as soon as one of these viruses surfaces again.
- CEPI also intends to fund vaccine platforms—technologies like harmless viral vectors or messenger RNA that can serve as backbones for a variety of vaccines.
- It has has received $100 million commitments from Wellcome Trust and the Bill & Melinda Gates Foundation, and the governments of Germany, Japan and Norway have pledged to contribute additional $260 million.
About Coalition for Epidemic Preparedness Innovations (CEPI)
- CEPI is a public-private alliance to finance and coordinate the development of new vaccines to prevent and contain infectious disease epidemics.
- It plans to develop early phases of vaccines without knowing the details for the form in which the deadly infection will appear but to cut down the time to tailor the eventual vaccine to be effective to epidemic.
- CEPI’s plan includes preparations for possible outbreaks of Marburg fever, Lassa fever, MERS, SARS, Nipah virus, Rift Valley fever, chikungunya, and others.
- It is being funded by the Wellcome Trust, t Bill and Melinda Gates Foundation, World Economic Forum (WEF), Governments of Norway, Japan, India (Department of Biotechnology) and Germany.